Brain natriuretic peptide (BNP) level is closely related to the extent of left ventricular sympathetic overactivity in chronic ischemic heart failure

Internal Medicine

Volumn 48, Issue 6, 2009, Pages 393-400

  Sakata, Kazuyuki ^a   Iida, Kei ^a   Mochiduki, Nao ^a   Nakaya, Yoshihiro ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

123 I meta iodobenzylguanidine imaging; Brain natriuretic peptide; Chronic ischemic heart failure; Left ventricular sympathetic overactivity

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ACETYLSALICYLIC ACID; ANGIOTENSIN II; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIGOXIN; DIURETIC AGENT; ENALAPRIL; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; METOPROLOL; NEUROHORMONE; NORADRENALIN; RENIN; TICLOPIDINE; VALSARTAN;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; BLOOD SAMPLING; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; GATED IMAGING; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE SIZE; HEART MUSCLE ISCHEMIA; HORMONE RELEASE; HUMAN; ISCHEMIC HEART DISEASE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PATIENT CODING; SYMPATHETIC TONE;

AGED; AGED, 80 AND OVER; CARDIAC-GATED SINGLE-PHOTON EMISSION COMPUTER-ASSISTED TOMOGRAPHY; CHEMILUMINESCENT MEASUREMENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE PROGRESSION; ELECTROCARDIOGRAPHY; EPINEPHRINE; FEMALE; FOLLOW-UP STUDIES; HEART CATHETERIZATION; HEART FAILURE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; NOREPINEPHRINE; RADIOIMMUNOASSAY; RENIN; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; SYMPATHETIC NERVOUS SYSTEM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 67650082411     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.1599     Document Type: Article

References (37)

1. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819-823, 1984.
2. Imamura Y, Fukuyama T, Mochizuki T, Miyagawa M, Watanabe K; Ehime MIBG Heart Failure Study Investigators. Prognostic value of iodine-123-metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. Jpn Circ J 65: 155-160, 2001.
3. Yamada T, Shimonagata T, Fukunami M, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol 41: 231-238, 2003.
4. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 26: 1257-1263, 1995.
5. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96: 509-516, 1997.
6. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330: 625-627, 2005.
7. Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 37: 1221-1227, 2001.
8. Woods RL. Cardioprotective functions of atrial natriuretic peptide and B-type natriuretic peptide: a brief review. Clin Exp Pharmacol Physiol 31: 791-794, 2004.
9. Liang F, Wu J, Garami M, Gardner DG. Mechanical strain increases expression of the brain natriuretic peptide gene in rat cardiac myocytes. J Biol Chem 272: 28050-28056, 1997.
10. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135 (5 Pt 1): 825-832, 1998.
11. He Q, Wu G, Lapointe MC. Isoproterenol and cAMP regulation of the human brain natriuretic peptide gene involves Src and Rac. Am J Physiol Endocrinol Metab 278: E1115-E1123, 2000.
12. Imamura Y, Ando H, Mitsuoka W, et al. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol 26: 1594-1599, 1995.
13. 123I-MIBG. J Nucl Med 40: 6-11, 1999.
14. 123I-metaiodobenzylguanidine scintigraphy. Metabolism 56: 919-924, 2007.
15. Sakata K, Yoshida H, Obayashi K, et al. Effects of losartan and its combination with quinapril on the cardiac sympathetic nervous system and neurohormonal status in essential hypertension. J Hypertens 20: 103-110, 2002.
16. Sakata K, Mochizuki M, Yoshida H, et al. Cardiac sympathetic dysfunction contributes to left ventricular remodeling after acute myocardial infarction. Eur J Nucl Med 27: 1641-1649, 2000.
17. Matsunari I, Schricke U, Bengel FM, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation 101: 2579-2585, 2000.
18. 123I-MIBG uptake in idiopathic ventricular tachycardia and fibrillation. J Nucl Med 40: 1-5, 1999.
19. Germno G, Kavanagh P, Su HT, et al. Automatic reorientation of three dimensional transaxial myocardial perfusion SPECT images. J Nucl Med 36: 1107-1114, 1995.
20. Cockcroft DW, Gault MH. Prediction of creatine clearance from serum creatine. Nephron 16: 31-41, 1976.
21. Voelker JR, Cobb SL, Bowsher PR. Improved HPLC-radioimmunoassay for quantifying angiotensin II in plasma. Clin Chem 40: 1537-1543, 1994.
22. Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 12: 1252-1258, 1988.
23. Gao DW, Talke PO, Dae MW. Effects of reduced sympathetic activity on myocardial metaiodobenzylguanidine (MIBG) washout. J Auton Pharmacol 21: 159-164, 2001.
24. Glowniak JV. Cardiac studies with metaiodobenzylguanidine: a critique of methods and interpretation of results. J Nucl Med 36: 2133-2137, 1995.
25. Wiese S, Breyer T, Dragu A, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation 102: 3074-3079, 2000.
26. Nakagawa K, Umetani K, Fujioka D, et al. Correlation of plasma concentrations of B-type natriuretic peptide with infarct size quantified by tomographic thallium-201 myocardial scintigraphy in asymptomatic patients with previous myocardial infarction. Circ J 68: 923-927, 2004.
27. Cochet A, Zeller M, Cottin Y, et al. The extent of myocardial damage assessed by contrast-enhanced MRI is a major determinant of N-BNP concentration after myocardial infarction. Eur J Heart Fail 6: 555-560, 2004.
28. 99mTc-sestamibi gated-single photon emission tomography. Clin Chem Lab Med 45: 226-231, 2007.
29. Tateishi J, Masutani M, Ohyanagi M, Iwasaki T. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol 23: 776-780, 2000.
30. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352: 666-675, 2005.
31. Goetze JP, Christoffersen C, Perko M, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 17: 1105-1107, 2003.
32. Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. Is B-type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the Heart and Soul Study. Am J Med 116: 561-563, 2004.
33. Cochet A, Zeller M, Cottin Y, et al. The extent of myocardial damage assessed by contrast-enhanced MRI is a major determinant of N-BNP concentration after myocardial infarction. Eur J Heart Fail 6: 555-560, 2004.
34. Hokimoto S, Yasue H, Fujimoto K, et al. Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction. Circulation 94: 1513-1518, 1996.
35. Yoshimura M, Yasue H, Ogawa H. Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure. Can J Physiol Pharmacol 79: 730-735, 2001.
36. Parthenakis FI, Patrianakos A, Prassopoulos V, et al. Relation of cardiac sympathetic innervation to proinflammatory cytokine levels in patients with heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 91: 1190-1194, 2003.
37. Zucker IH, Pliquett RU. Novel mechanisms of sympatho-excitation in chronic heart failure. Heart Fail Monit 3: 2-7, 2002.